Canton

DXL Group Promotes Stacey Jones to Chief Human Resources Officer

Retrieved on: 
Friday, February 19, 2021
Articles, Economy, Business, CHRO, Chief human resources officer, Destination XL Group, OTC Markets Group, Chief executive officer

CANTON, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (OTCQX: DXLG) announced today that Stacey Jones has been promoted to Chief Human Resources Officer (CHRO), effective February 21, 2021.

Key Points: 
  • CANTON, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (OTCQX: DXLG) announced today that Stacey Jones has been promoted to Chief Human Resources Officer (CHRO), effective February 21, 2021.
  • From 2001 to 2018, Jones held a variety of positions with increasing responsibility in both Retail Operations and Human Resources for DXLG.
  • Since 2018 she has served as DXLGs Vice President, Managing Director of Human Resources.
  • She has strengthened our commitment to make DXLG an even better place to work, said Harvey Kanter, President and Chief Executive Officer.

Destination XL Group, Inc. to Announce Fourth Quarter and Fiscal 2020 Financial Results on March 18, 2021

Retrieved on: 
Thursday, February 18, 2021
Destination XL Group, Companies, DXL, Plus-size clothing, Service companies, XL, Economy of the United States

CANTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (OTCQX: DXLG), the largest omni-channel specialty retailer of big and tall mens clothing, announced today it will release its fourth quarter and fiscal 2020 financial results before the market opens on Thursday, March 18, 2021.

Key Points: 
  • CANTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (OTCQX: DXLG), the largest omni-channel specialty retailer of big and tall mens clothing, announced today it will release its fourth quarter and fiscal 2020 financial results before the market opens on Thursday, March 18, 2021.
  • To listen to the live webcast, visit the " Investor Relations " section of the Company's website.
  • Destination XL Group, Inc. is the largest retailer of mens clothing in sizes XL and up, with operations throughout the United States as well as in Toronto, Canada.
  • In addition to DXL Big + Tall retail and outlet stores, subsidiaries of Destination XL Group, Inc. also operate Casual Male XL retail and outlet stores, and e-commerce sites, including DXL.com .

Organogenesis Appoints David C. Francisco as Chief Financial Officer

Retrieved on: 
Tuesday, February 16, 2021
Developmental biology, Embryology, Organogenesis, Lluís Companys, Spanish politicians, Government of Spain, Politicians

In connection with the hiring of Mr. Francisco, Henry Hagopian will serve as the Companys Senior Vice President of Finance and Treasurer.

Key Points: 
  • In connection with the hiring of Mr. Francisco, Henry Hagopian will serve as the Companys Senior Vice President of Finance and Treasurer.
  • I am pleased to welcome Dave to the Organogenesis executive leadership team, said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis.
  • Dave brings strong strategic, financial, and operational leadership across multiple business areas and over 25 years of finance and accounting experience.
  • Organogenesis is an impressive organization with compelling growth opportunities, said David Francisco.

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

Retrieved on: 
Tuesday, February 9, 2021
Bioactive, Biomaterial

Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time.

Key Points: 
  • Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time.
  • Live audio webcasts of the conference presentations will be accessible by visiting the Upcoming Events section on the Investor Relations page of Organogenesiss website www.organogenesis.com.
  • Archives of the webcasts will be available for replay following the conference for approximately 30 days.
  • Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021

Retrieved on: 
Monday, February 8, 2021
Finance, Money, Economy, Corporate finance, Stock market, Conference call, Investor relations, Investor, Piccinino

Management will host a conference call at 5:00 p.m. Eastern Time on March 16 to discuss the results of the quarter and the fiscal year, and provide a corporate update with a question and answer session.

Key Points: 
  • Management will host a conference call at 5:00 p.m. Eastern Time on March 16 to discuss the results of the quarter and the fiscal year, and provide a corporate update with a question and answer session.
  • Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 6766924.
  • A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com .
  • Investor Inquiries: Westwicke Partners Mike Piccinino, CFA [email protected] Press and Media Inquiries: Organogenesis Lori Freedman [email protected]

Destination XL Group, Inc. Announces $5 Million Registered Direct Offering

Retrieved on: 
Friday, February 5, 2021
Destination XL Group, Companies, Retailing, Retailers, DXL, XL, Outlet store

Gross proceeds to the Company are expected to be approximately $5.0 million, before deducting placement agent fees and other estimated offering expenses.

Key Points: 
  • Gross proceeds to the Company are expected to be approximately $5.0 million, before deducting placement agent fees and other estimated offering expenses.
  • The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
  • Destination XL Group, Inc. is the largest retailer of mens clothing in sizes XL and up, with operations throughout the United States as well as in Toronto, Canada.
  • In addition to DXL Big + Tall retail and outlet stores, subsidiaries of Destination XL Group, Inc. also operate Casual Male XL retail and outlet stores, and e-commerce sites, including DXL.com.

Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis

Retrieved on: 
Thursday, January 14, 2021
Clinical research, Design of experiments, Medical research, Arthritis, Clinical trials, Health sciences, Methodology, Osteoarthritis, ReNu, Placebo-controlled study, Randomized controlled trial

We are very pleased to have initiated our ReNu pivotal Phase 3 trial, said Patrick Bilbo, Chief Operating Officer for Organogenesis.

Key Points: 
  • We are very pleased to have initiated our ReNu pivotal Phase 3 trial, said Patrick Bilbo, Chief Operating Officer for Organogenesis.
  • We look forward to leveraging our RMAT designation to work closely with the FDA to expedite the review of ReNu as the study progresses.
  • The Phase 3 study is a prospective, double-blind, multicenter, placebo-controlled, parallel group, randomized control trial (RCT) of ReNu in 474 subjects with moderate to severe symptomatic knee osteoarthritis.
  • Patients will be randomized to either a single intra-articular (IA) injection of saline (placebo control) or a single injection of ReNu.

Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020

Retrieved on: 
Wednesday, January 13, 2021
Earnings before interest, taxes, depreciation and amortization, Fundamental analysis, Private equity, Profit, Finance, Income, Money

Fourth Quarter 2020 Preliminary Financial Results Summary:

Key Points: 
  • Fourth Quarter 2020 Preliminary Financial Results Summary:
    Net revenue of between $104.6 million and $106.0 million for the three months ended December 31, 2020, up 40% to 42% compared to net revenue of $74.6 million for the three months ended December 31, 2019.
  • The Company expects to report positive GAAP net income and positive Adjusted EBITDA for the three months ended December 31, 2020.
  • Fiscal Year 2020 Preliminary Financial Results Summary:
    Net revenue of between $336.1 million and $337.5 million for the twelve months ended December 31, 2020, up approximately 29% compared to net revenue of $261 million for the twelve months ended December 31, 2019.
  • The Company expects to report positive GAAP net income and positive Adjusted EBITDA for the full fiscal year 2020 period.

Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee

Retrieved on: 
Monday, January 11, 2021
Life sciences, Health sciences, Pharmacy, Food and Drug Administration, Emerging technologies, Fast track, Breakthrough therapy, Osteoarthritis, Therapy, Regenerative medicine, Biopharmaceutical, Biomaterial

The FDA created the RMAT designation program to expedite development and review of regenerative medicine therapies intended to treat, modify, reverse or cure a serious or life-threatening disease or condition.

Key Points: 
  • The FDA created the RMAT designation program to expedite development and review of regenerative medicine therapies intended to treat, modify, reverse or cure a serious or life-threatening disease or condition.
  • Securing RMAT designation is a significant milestone for ReNu that underscores the potential impact of this therapy for knee osteoarthritis, said Gary S. Gilheeney, Sr., President and CEO of Organogenesis.
  • RMAT designation includes all of the benefits of the Fast Track and Breakthrough Therapy designation programs.
  • Organogenesis is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Destination XL Group, Inc. Holiday Sales Results and Guidance

Retrieved on: 
Monday, January 11, 2021
Destination XL Group, Companies

CANTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc.(OTCQX:DXLG), the largest omni-channel specialty retailer of big and tall men's apparel, today announced the following results for the 9-week holiday sales period ended January 2, 2021 (unaudited):

Key Points: 
  • CANTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Destination XL Group, Inc.(OTCQX:DXLG), the largest omni-channel specialty retailer of big and tall men's apparel, today announced the following results for the 9-week holiday sales period ended January 2, 2021 (unaudited):
    Total sales decreased 23.9% to $78.4 million compared to $103.1 million for the 9-week holiday sales period ended January 4, 2020.
  • Direct sales are defined as sales that originate online, whether through our website, at the store level or through a third party marketplace.
  • Based on the holiday sales results and expectations for the remainder of the fourth quarter, the Company expects total sales for fiscal 2020 of $317.0 million to $319.0 million, with comparable sales in our omni-channel retail business for the full year to be down 32.6% to 32.9%.
  • Sales from our wholesale business are not part of the Companys comparable sales calculation.